Basophil identification and the propensity of these cells for immune activation was also confirmed in a cohort of 53 ovarian cancer patients with a wide range of tumour histologies and treatment histories [11], suggesting that the use of BAT in evaluating hypersensitivity to an IgE therapy is applicable to a broad spectrum of patients. The gene discussed is IGHE; the disease is ovarian carcinoma.